(237) A shared neoantigen melanoma vaccine formulated with a novel biodegradable liquid polymer

Introduction: Despite advances in immunotherapies, clinical treatments for metastatic melanoma remain limited. A neoantigen peptide mutation found on melanoma tumors, BRAF V600E, is a promising target for vaccines, as it is shared among nearly 50% of all melanoma patients [1]. Our objective is to develop a sustained release formulation of a mutant BRAF peptide vaccine via an injectable depot of a novel biodegradable hydrophobic liquid polymer (named “CAPRO”), aiming to achieve antigen-specific CD8 T cell responses.